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Inherited	 colorectal	 cancer	 covers	 two	main	 groups	 of	 cancers:	with	 and	without	
polyps,	which	are	(or	not)	major	manifestations	of	the	disease.	The	polyposis	syndromes	
are	divided	into	familial	adenomatous	polyposis	and	the	hamartomatous	polyposis	syn-









results	 in	uncontrolled	proliferation,	 the	development	of	cancer	 is	observed.	Sporadic	
colorectal	cancer	occurs	when	accumulation	of	multiple	mutations	is	present	(2).	






















the genetics of hereditary colorectal cancers
The	 hereditary	 colorectal	 cancers	 are	 familial	 adenomatous	 polyposis	 and	 hereditary	
non-polyposis	colorectal	cancers	(HNPCC).
Familial	adenomatous	polyposis	is	an	autosomal	dominantly	inherited	disease,	which	
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the genetics of sporadic colorectal cancer
The genetic changes, which may lead to sporadic colorectal cancer were first described 








Figure 3.1. Multistep process of tumorigenesis in the “suppressor” pathway






































some	 cancers	 (28).	There	 is	 also	 evidence	 that	 hypermethylation	 of	 promoter	 region	
of	hMLH1 leads	to	microsatellite	instability	(MSI)	in	non-hereditary	colorectal	cancers	
(29).	It	has	been	found	that	both	alleles	of	hMLH1 were hypermethylated in five out of 
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This model of tumorigenesis probably accounts for a significant proportion of serrated 
adenomas	(33)	and	is	termed	“serrated”	pathway.
The	 increasing	 knowledge	 on	 genetic	 changes	 in	 colorectal	 cancer	 tumorigenesis	
gives	the	opportunity	for	the	development	of	molecular	tools	for	prevention	and	early	
diagnosis.	Some	molecular	DNA-based	stool	 tests	are	under	 investigation	in	 terms	of	
their sensitivity and specificity. The main candidates for screening are single gene tests 
of	mutations	of k-ras	and	APC	and	multiple	gene	test,	which	used	a	panel	of	three	genes:	
p53, k-ras and	microsatelite	marker	BAT-26	(34,	35).	More	investigations,	however,	are	
Figure 3.2. Multiple pathways to colorectal cancer






ing	 35%	 to	 genetic	 predispositions	 and	 5%	 to	 environmental	 factors	 (36).	The	main	
risk	factors	for	colorectal	cancer	are	low	consumption	of	fruits	and	vegetables	(which	




(Causes of colorectal cancer).
There	are	several	medical	conditions	that	have	effect	on	colorectal	cancer	risk.	Some	
of them, like the use of non-steroidal anti-inflammatory drugs and hormone replacement 
therapy	decrease	it,	while	others,	especially	certain	diseases,	may	have	the	opposite	ef-
fect	(Table	3.1).
Table 3.1. Risk factors for colorectal cancer
	Intestinal polyp(s)






















first-degree relatives run twice as high risk of CRC, and the risk is higher if CRC was 
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Table 3.2. Symptoms in colorectal cancer
	Change in bowel habits
	Diarrhea
	Constipation
































	Fecal occult blood test (FOBT) unrehydrated
























$ – for cancer
* – for rectal cancer
** – genetic testing should be considered as one part of the clinical evaluation of patients who are suspected of 
having inherited colon cancer syndromes
The final diagnosis of colorectal cancer is based on histopathological examination of 
suspected	tissue	obtained	by	biopsy.








	Hereditary Non-Polyposis Colorectal Cancer 
(HNPCC)*
•	 AC-1 group A (with MMR deficiency; sho-
wed increased incidence of extracolonic 
cancers; previously Lynch II)
•	 AC-1 group B (without MMR deficiency; 
showed lower incidence of extracolonic 
cancers; previously Lynch I)
With polyps
	Familial Adenomatous Polyposis (FAP)
	Attenuated Familial Adenomatous Polyposis 
(AFAP)
	Mixed Polyposis Syndrome
	Ashkenazi I1307K colon cancer




•	 Familial Juvenile Polyposis
•	 Cowden’s disease
•	 Bannayan-Ruvalcaba-Riley syndrome
* new classification proposed by Lindor et al. (45) and based on the knowledge about MMR mutations and their 







Table 3.4. Clinical criteria for Hereditary Non-Polyposis Colorectal Cancer (HNPCC) (46, 47)
Amsterdam (I) criteria:
At least three relatives with histologically confirmed colorectal cancer and all of the following:
1) one affected person is a first-degree relative of the other two affected persons
2) two successive generations affected
3) at least one of the relatives with colorectal cancer diagnosed before 50 years of age
4) Familial Adenomatous Polyposis has been excluded
Modified Amsterdam (II) criteria:
At least three relatives with histologically confirmed HNPCC-associated* cancer and all of the following:
1) one affected person is a first-degree relative of the other two affected persons
2) two successive generations affected
3) at least one of the relatives with colorectal cancer diagnosed before 50 years of age
4) Familial Adenomatous Polyposis has been excluded
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Bethesda criteria:
The Amsterdam criteria or one of the following:
1) two cases of HNPCC-associated* cancer diagnosed in one patient, including synchronous or 
metachronous cancer
2) diagnosis of colorectal cancer and a first-degree relative with HNPCC-associated* cancer and/
or colonic adenoma (one case of cancer diagnosed before 45 years of age and adenoma diag-
nosed before 40 years of age
3) colon or endometrial cancer diagnosed before 45 years of age
4) right sided colon cancer that has an undifferentiated pattern (solid-cribriform) or signet-cell histo-
pathologic characteristics diagnosed before 45 years of age
5) adenomas diagnosed before 40 years of age
* HNPCC-associated cancers include: colorectal, endometrial, stomach, ovarian, pancreas, ureter or renal pel-
vis, biliary tract, and brain (usually glioblastoma as seen in Turcot syndrome) tumours, sebaceous gland adeno-
mas and keratoacanthomas in Muir-Torre syndrome, and carcinoma of the small bowel.
Screening
It	is	well	known	that	colorectal	cancer	screening	is	effective,	improves	surveillance	and	
provides life-saving benefits. The type of screening procedure and frequency of exami-
nation	is	related	to	the	risk	of	developing	colorectal	cancer	in	the	future,	and	this	depends	
mainly	on	the	individual	genetic	predisposition.	
Risk Screening method Age to begin screening Interval
Classical FAP (48) Sigmoidoscopy1 10–12 2 years1
Attenuated FAP (48) Colonoscopy 18–20 2 years1
HNPCC2 (49) Colonoscopy 20–25 1–2 years
Familial clustering of colorec-
tal cancer without evidence of 
MSI3 (49)
Colonoscopy
45–50 or 5–10 before age 
at diagnosis of first CRC 
in family
3–5 years
≥ 2 first-degree relatives with 
colorectal cancer or adeno-
matous polyps at age < 60
Colonoscopy
40 or 10 before age at 
diagnosis of first CRC  
in family
3–5 years
First-degree relative with 
colorectal cancer or adeno-





























1 and 5 years
5–10 years
10 years
FAP – familial adenomatous polyposis; HNPCC – hereditary non-polyposis colorectal cancer; MSI – microsatel-
lite instability; CRC – colorectal cancer; DCBE – double-contrast barium enema.
1 once adenomas are detected annual colonoscopy should be performed until colectomy is planned,
2 at the age 30–35 other screening methods are recommended for extracolonic localisation, like gynaecologi-
cal examination, transvaginal ultrasound, aspiration biopsy, gastroduodenoscopy, abdominal ultrasound, and if 
urinary tract cancer runs in the family also urinalysis and urine cytology,
3 Amsterdam positive families,
4 combined testing (e.g., FOBT annually and sigmoidoscopy every 5 years) is preferred over either annual FOBT 
or sigmoidoscopy every 5 years alone.





enocarcinoma specified cancers (13%) (carcinoid, small cell carcinoma, undifferentiated 
carcinoma),	and	sarcomas	(0.1%)	(leiomyosacromas,	angiosarcomas,	lyposarcomas,	and	
fibrosarcomas) (50).
The staging of colorectal cancer is based on Duke’s classification (Fig. 3.3) modified 
later	by	Astler-Coller:
•	 Duke A – tumour penetrates into the mucosa of the bowel but not infiltrates muscula-
ris	propria,
•	 Duke	B1	–	tumour	penetrates	into	but	not	through	the	muscularis	propria,







Figure 3.3. The Duke’s classification of colorectal cancer
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The	American	Joint	Committee	on	Cancer	(AJCC)	introduced	the	system	classify-
ing tumours into the four (in fifth edition) and into seven (in sixth edition) stages, which 
depend	on	the	tumour	(T),	lymph	nodes	(N)	and	metastases	(M)	features:
Tumour (T) Lymph nodes (N) Metastasis (M)
T1 – tumor invades submucosa
T2 – tumor invades muscularis 
propria
T3 – tumor invades through the 
muscularis propria into the 
subserosa, or into the peri-
colic or perirectal tissues
T4 – tumor directly invades 
other organs or structures, 
and/or perforates*
N0 – no regional lymph node 
metastasis
N1 – metastasis in 1 to 3 regio-
nal lymph nodes
N2 – metastasis in 4 or more 
regional lymph nodes
M0 – no distant metastasis
M1 – Distant metastasis present
* The most likely organs to experience metastasis from colorectal cancer are the lungs and liver.
Stages as defined by the American Joint Committee on Cancer (AJCC) are as fol-
lows:
T N M
AJCC – 5th edition
I T1 or T2 N0 M0
II T3 or T4 N0 M0
III any T N1 M0
IV any T any N M1
AJCC – 6th edition
I T1 or T2 N0 M0
IIa T3 N0 M0
IIb T4 N0 M0
IIIa T1 or T2 N1 M0
IIIb T3 or T4 N1 M0
IIIc any T N2 M0
IV any T any N M1
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* NOS = not otherwise specified; 1% of cases was overlapping sites
Figure 3.4. Distribution of colorectal cancer by tumour site and 5-year survival rates (in parenthesis) by 
regions (USA and Europe)
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tions, which influence the effectiveness of screening, diagnosis, treatment, and finally 
the	survival	rate.
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